Drug Profile
Hyaluronidase/rituximab - Roche
Alternative Names: MabThera SC; Rituxan Hycela; RITUXAN SC; Rituximab subcutaneousLatest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Halozyme Therapeutics; Roche
- Class Antineoplastics; Glycoside hydrolases; Monoclonal antibodies; Polysaccharide lyases
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma
- Preregistration Unspecified
Most Recent Events
- 01 Nov 2022 Preregistration for Unspecified in China (SC)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, First-line therapy) in Argentina (SC, Injection)
- 28 Feb 2019 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Combination therapy, First-line therapy) in Australia (SC, Injection)